Pathways such as the PI3K/AKT/mTOR pathway’s inhibitor with limited response may be further linked to the activation of the compensatory cascade of mitogen-activated protein kinase (MAPK), and the relevant research using preclinical models of prostate cancer demonstrates that the cancer is increasing enormously after blocking both channels together (89). This evidence concerns the gene AKT1 and prostate cancer.